Study of S-1 Plus LV for Untreated Metastatic Colorectal Cancer
This is a multicenter study designed to evaluate the response rate of S-1 plus Leucovorin (1 week on and 1 week off) as first -line treatment for patients with metastatic colorectal cancer.
Colorectal Cancer
DRUG: S-1 plus LV (The combination therapy of S-1 and Leucovorin)
Overall Response Rate (ORR), During chemotherapy
Safety, During chemotherapy|Progression free survival (PFS), Until progression|Disease control rate(DCR), During chemotherapy|Time to treatment failure (TTF), Until progression|Overall survival (OS), Over two years from registration|Feasibility, During chemotherapy|Pharmacokinetics, During chemotherapy
This is a multicenter study designed to evaluate the response rate of S-1 plus Leucovorin (1 week on and 1 week off) as first -line treatment for patients with metastatic colorectal cancer.